<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238936</url>
  </required_header>
  <id_info>
    <org_study_id>ATADEK-2020/02</org_study_id>
    <nct_id>NCT04238936</nct_id>
  </id_info>
  <brief_title>GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist</brief_title>
  <official_title>Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serum amyloid A and Interleukin-1 (IL-1) receptor antagonist (A-SAA and IL-1Ra) values;

        -  Comparison of pregnant women with and without GDM diagnosis

        -  Comparison of insulin therapy and diet-regulated GDM patients

        -  Comparison of pregnant women with and without LGA (large gestational age)

        -  Comparison of pregnant women with and without polyhydroamnios

        -  Investigation of its effect on pregnancy prognosis

        -  In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity
           of both parameters and cut off values.

      (In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and
      IL-1Ra levels).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Actual">May 20, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum amyloid A</measure>
    <time_frame>1 week</time_frame>
    <description>Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 (IL-1) receptor antagonist</measure>
    <time_frame>1 week</time_frame>
    <description>Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>study group ; Patients with gestational diabetes</arm_group_label>
    <description>Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group ; healthy pregnant women</arm_group_label>
    <description>Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum amyloid A values</intervention_name>
    <description>Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.</description>
    <arm_group_label>control group ; healthy pregnant women</arm_group_label>
    <arm_group_label>study group ; Patients with gestational diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)</intervention_name>
    <description>Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.</description>
    <arm_group_label>study group ; Patients with gestational diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Serum amyloid A (SAA) and Interleukin-1 (IL-1) receptor antagonist level will be examined
        in the study group consisting of pregnant women with GDM diagnosis and in the control group
        consisting of healthy pregnant women.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with 50 gr OGTT + 100 gr OGTT + at 24-28 weeks of gestation

          -  Patients with 75 gr OGTT + at 24-28 weeks of gestation

          -  18-42 years pregnant women

        Exclusion Criteria:

          -  any infection

          -  Any known fetal chromosomal or structural anomaly

          -  Preterm membrane rupture

          -  Preterm delivery

          -  Preeclampsia or eclampsia

          -  Placenta previa
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kanuni Sultan Süleyman Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>33404</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Pınar Kadirogulları</investigator_full_name>
    <investigator_title>principal investigator, Pınar kadirogullari, M.D, Department of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Gestational Diabetes</keyword>
  <keyword>Serum amyloid A</keyword>
  <keyword>Interleukin-1 (IL-1) receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

